Skip to content

CorMedix CRMD Additional Paid-In Capital

Additional Paid-In Capital at other companies

Pfizer logo
PfizerPFE
$94.77B+1.0%
ITG
Integer HoldingsITGR
$755.87M+0.2%
IAR
Integra LifeSciencesIART
$1.34B+1.3%
Emergent Biosolutions logo
Emergent BiosolutionsEBS
$944.5M+1.5%
ICU Medical logo
ICU MedicalICUI
$1.47B+3.5%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$1.7B+90.5%

Other financials

Income statement

See full
Revenue$127.4M+226%
Gross profit$115.4M+207%
Operating income$63.7M+216%
Net income$38.6M+87.0%
EPS (diluted)$0.43+43.3%

Balance sheet

See full
Cash & equivalents$179.1M+170%
Total debt$4.3M+729%
Total equity$437.0M+280%
Total assets$815.6M+445%

Cash flow

See full
Operating cash flow$42.4M+115%
CapEx$729.0K+7,190%
Free cash flow$41.7M+111%

Valuation

See full
Market cap$605.65M-34.4%
P/E3.4×
P/S1.5×-9.6×

Profitability

See full
Gross margin91.9%-3.5pp
Operating margin48.4%
Net margin45.2%
FCF margin48.7%+38.8pp

Returns & leverage

See full
Return on equity65.6%
Debt / equity0.0×
Current ratio-1.2×

Where this comes from

Reported directly by CorMedix in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: CorMedix’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CorMedix's additional paid-in capital?
CorMedix (CRMD) reported additional paid-in capital of $574.94M in Q1 2026.
How has CorMedix's additional paid-in capital changed year-over-year?
CorMedix's additional paid-in capital increased by 32.6% year-over-year, from $433.72M to $574.94M.
What is the long-term trend for CorMedix's additional paid-in capital?
Over 5 years (2020 to 2025), CorMedix's additional paid-in capital has grown at a 17.3% compound annual growth rate (CAGR), from $261.54M to $581.8M.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.